AstraZeneca rockets toward Tagrisso sales target with another survival win

AstraZeneca already has a Tagrisso approval for patients with previously untreated, EGFR-mutated lung cancer. But its shoring up its case with some clutch new data. Friday, the British drugmaker said Tagrisso had beaten out Roches rival drug Tarceva and AstraZenecas own Iressa at helping patients live longer. The showing came as part of the phase 3 Flaura trial the same study that helped net Tagrisso its approval last year based on a reduction in the risk of disease progression. That overall survival win could be a crucial stat for oncologists deciding which drug to pick. And thanks to the initial round of Flaura data, Tagrisso is already steamrolling. In the first half of 2019, it reeled in $1.41 billion in global sales, a 92% jump over the year-ago period at constant exchange rates. U.S. sales also ramped up between Q1 and Q2, swelling by 16% to reflect “continued underlying demand growth,” AstraZeneca said in a financial filing. That’s not to say it’s without competition, though. Just under a year ago, Pfizer snagged an FDA green light for once-failed Vizimpro in the first-line arena. While that drug is putting up tiny numbers, it’s still been a thorn in AstraZeneca’s side in the U.K., where cost watchdogs recently backed it for NHS use while shutting Tagrisso out.

Spotlight

Spotlight

Related News